老年冠心病患者血清同型半胱氨酸与纤溶酶活性

背景同型半胱氨酸已成为动脉粥样硬化的独立危险因子,它可能通过破坏内皮细胞的结构和功能从而导致动脉粥样硬化.目的探讨同型半胱氨酸对老年冠心病患者纤溶酶活性的影响.设计以冠心病患者为研究对象,健康人群为对照组的病例-对照.单位一所大学医院的综合科及心内科.对象本研究于首都医科大学附属北京朝阳医院综合科及心内科完成.选择2001-12/2003-8本院心内科及综合科门诊及住院患者177例,根据冠状动脉造影结果分为冠心病组91例,其中男50例,女41例,平均年龄(66±6)岁;冠状动脉造影阴性组86例,其中男43例,女43例,平均年龄(60±6)岁.正常对照组为同期于本院门诊体检的健康中年人85例,其中男43例,女42例,平均年龄(55±5)岁.方法收集外周血,检测血浆中的组织型纤溶酶原激活剂、纤溶酶原激活物抑制剂1和血管性血友病因子的活性,用酶免疫试验法测同型半胱氨酸,并计算纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂活性比值.主要观察指标血清同型半胱氨酸水平及血浆组织型纤溶酶原激活剂、纤溶酶原激活物抑制剂1、血管性血友病因子活性,纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂的比值.结果冠状动脉病变组同型半胱氨酸,纤溶酶原激活物抑制剂1,纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂,血管性血友病因子均明显高于冠状动脉造影阴性组及正常对照组(P＜0.01),组织型纤溶酶原激活剂水平显著低于对照组(P＜0.01);从相关分析看,同型半胱氨酸与纤溶酶原激活物抑制剂1,纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂,血管性血友病因子呈正相关,与组织型纤溶酶原激活剂呈负相关.结论老年冠心病患者其血清同型半胱氨酸增高的同时,纤溶酶活性受损;同型半胱氨酸与纤溶酶原激活物抑制剂1,血管性血友病因子呈正相关,与组织型纤溶酶原激活剂呈负相关;同型半胱氨酸可能是冠状动脉早期病变的预报因子,可为冠心病的一级预防和早期康复措施介入提供相关实验数据.

Homocysteine and fibrinolysin in elderly patients with coronary heart disease

BACKGROUND: Homocysteine(HCY) is emerging as an independent risk factor for atherosclerosis. Its damage to the structure and function of endothelial cell(EC) is seemingly an important mechanism that leads to atherosclerosis.OBJECTIVE: To investigate the effect of HCY on fibrinolysis in elderly patients with coronary heart disease(CHD).DESIGN: A case-controlled study based on CHD patients and normal people as control group.SETTING: Department of general internal medicine and department of cardiology in a university hospital.PARTICIPANTS: The study was completed in the Department of Gerontology Internal Medicine and Department of Cardiology, Beijing Chaoyang Hospital, Capital University of Medical Science. Altogether 177 inpatients and outpatients from this hospital during December 2001 to August 2003 were selected and divided into three groups according to the results of coronary angiography(CAG): CHD group( n = 91 ) with 50 males and 41 females with the mean age of(66 ± 6) years, negative CAG group( n = 86) with 43 males and 43 females with the mean age of(60 ± 6) years, and normal control group( n = 85) with 43 healthy males and 42 healthy females with the mean age of(55± 5) years.METHODS: Peripheral blood samples were collected. ELISA double antibody method was applied to test tissue-type plasminogen activator(t-PA), plasminogen activator inhibitor-1 (PAI-1) and yon Willebrand factor(vWF). HCY was assayed with EIA method and the ratio of PAI-1 to t-PA was calculated.MAIN OUTCOME MEASURES: HCY level, t-PA, PAI-1 and vWF activities, and the ratio of PAI-1 to t-PA.RESULTS: The levels of HCY, PAI-1, PAI-1/t-PA and vWF in CHD group were significantly higher than those in negative CAG group and normal control group( P ＜ 0.01 ); however, the level of t-PA was significantly lower than that in control group( P ＜ 0. 01) . HCY was positively correlated with PAI-1,PAI-1 / t-PA and vWF, while it was negatively correlated with t-PA.CONCLUSION: The increase of serum HCY is accompanied with fibrinolytic dysfunction. HCY is positively correlated with PAI-1 and vWF but negatively correlated with t-PA. Therefore, HCY is a predictor for early coronary lesions,and can provide related laboratory data for the primary prevention and early treatment of CHD.